Doxorubicin induced cardiomyopathy

Summary

Doxorubicin induced cardiomyopathy (MONDO:0023006) is a disease and 9 clinical trials. Top therapeutic interventions include gadoterate meglumine. A subtype of cardiomyopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	doxorubicin induced cardiomyopathy
Mondo ID	MONDO:0023006
Is cancer (heuristic)	no

Disease family

This is a subtype of cardiomyopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › cardiomyopathy › doxorubicin induced cardiomyopathy

Related subtypes (11): Keshan disease, intrinsic cardiomyopathy, extrinsic cardiomyopathy, idiopathic cardiomyopathy, familial cardiomyopathy, non-compaction cardiomyopathy, Chagas cardiomyopathy, Uhl anomaly, Tako-tsubo cardiomyopathy, cardiomyopathy due to anthracyclines, autoimmune cardiomyopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	3
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05792293	PHASE2/PHASE3	UNKNOWN	Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
NCT06427226	PHASE2	RECRUITING	Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
NCT07370506	PHASE1/PHASE2	NOT_YET_RECRUITING	Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
NCT02677714	PHASE2	TERMINATED	99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer
NCT06092606	PHASE2	UNKNOWN	A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
NCT02796365	Not specified	COMPLETED	Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy
NCT03000036	Not specified	COMPLETED	Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients
NCT04461223	Not specified	UNKNOWN	Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
NCT05731375	Not specified	COMPLETED	Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GADOTERATE MEGLUMINE	4	1
CHEMBL443232	0	1